World Peptide Therapeutics Congress 2027
Where the architects of the next $100B in peptide medicine — post-GLP-1 science, AI-designed molecules, oral breakthroughs & radiopharmaceuticals — meet regulators, clinicians, and capital to decide what reaches patients by 2030.
3rd–5th March 2027 | Boston, MA
The Peptide Era Has Been Proven. Now It Gets Built.
The World Peptide Therapeutics Congress 2027 is the flagship gathering for the scientists, executives, regulators, and investors building peptide medicine’s second decade.The first wave is complete: incretins reshaped obesity care, oral peptides reached patients, radioligands became oncology’s fastest-growing category, and AI-designed molecules entered the clinic. The question is no longer “can peptides be drugs?” — it’s “who will build, deliver, scale, and fund the next generation?”
Across 3 days, 5 tracks, and 90+ sessions, the Congress delivers what no other peptide event does:
🔬 First, not repeated. Unpublished Phase 1/2 data, live platform disclosures, and regulatory updates — presented here before journals and before any other 2027 conference.
⚖️ The whole value chain in one room. Discovery science, delivery & formulation, CMC at ton-scale, regulatory implementation, clinical translation, and deal-making — integrated, because that’s how drugs actually succeed.
🤝 A deal venue, not a lecture hall. An AI-matched 1:1 partnering system, investor reverse pitches, and a curated audience where 70% hold Director-level titles or above and service providers are capped — so every conversation has pipeline potential.
🚫 A No-Pitch Charter. Vendor content is limited, flagged, and never occupies main-stage science. Your time is treated as the asset it is.
Whether you’re hunting the post-GLP-1 blockbuster, scaling green manufacturing to tons, navigating finalized ICH guidance, or deploying capital in the peptide supercycle — this is the room where 2027’s roadmap gets written.
80+ Speakers // 600+ Peer-Reviewed Attendees // 5 Dedicated Tracks // 40+ Countries // 1,200+ Pre-Scheduled 1:1 Meetings
The 2027 Summit Will Address:
- The Post-GLP-1 Frontier: Amylin Co-Agonists, Muscle Preservation & the Weight-Maintenance Era
AI-Designed Peptides With Clinical Data — The Applied Reality of Generative Drug Design
Second-Generation Oral Peptide Science: Design Rules Written by Approved Products
Radioligands & Peptide-Drug Conjugates: The Post-PSMA Expansion
In Vivo Cell Reprogramming & Extrahepatic RNA Delivery — Peptides as Genetic Medicine Vehicles
Drugging the Undruggable: Molecular Glue Peptides, De Novo Miniproteins & Peptide Degraders
Manufacturing at Blockbuster Scale: Green CMC, Tons-Throughput & Sustainable Supply
The Regulatory Implementation Era: ICH Q2(R2), Q14, M10 & New Peptide-Specific Guidances
Clinical First-Disclosures: Oncology, Immunology & Pandemic Preparedness
Capital, M&A & IP in the Peptide Supercycle
What's New for 2027?
Hear It Here First — Or Hear It Nowhere
Dedicated first-disclosure slots with managed embargoes: Phase 2 readouts, platform data, and regulatory interpretations debuting on our stage up to 12 months before they appear at competing conferences or in journals.
A Room Engineered for ROI
- 70% Director-level and above — verified titles, not inflated badges
- Service-provider attendance capped at 30% — so your networking time isn’t consumed by vendors
- AI-matched 1:1 partnering system with 25+ guaranteed, pre-scheduled meetings before you land
Get Answers You Can't Google
Advisory committee sessions, compendial-body workshops, and former regulators answering your CMC, immunogenicity, and filing questions directly — in rooms of 30, not auditoriums of 600.
The Clinician's Verdict
Practicing oncologists and endocrinologists grade the peptide pipeline live — telling you, before you spend $50M, what treating physicians will actually prescribe.
See 2028's Topics in 2027
In vivo T-cell reprogramming, molecular glue macrocycles, ton-scale green manufacturing, AI-inventorship IP — the modalities and constraints that will define the next deal cycle, programmed before any other event touches them.
Measurable Outcomes, Guaranteed
Average delegate reports: 27 new qualified contacts, 9 follow-up meetings booked on-site, and 3 pipeline decisions accelerated per event. If your meeting count isn’t met, we credit your registration. That’s how confident we are.
The Highest-ROI Audience in Peptides — Because We Protect It
Scarcity By Design — Value By Default
Sponsor and exhibitor slots are capped and service-provider attendance limited to 30%. Your competitors at other events are shouting into rooms full of other vendors. Here, you’re one of a deliberately limited set and every booth conversation happens with a buyer, not a seller.
Reach Deciders, Not Attendees
Our delegates hold budget: 70% Director+, 40% from large pharma, 25% from funded biotech actively outsourcing. The people evaluating CDMO transfers, hiring discovery platforms, and releasing 2028 R&D budgets are in this room with meeting slots reserved for you.
Sponsorship That Feeds Your Pipeline, Not Just Your Logo
- Guaranteed 1:1 meetings with pre-qualified targets from your TAM — AI-matched, confirmed in advance
- Investor access track for platforms seeking Series B–C or licensing partners
- Reverse-pitch sessions where pharma BD teams state exactly what they want to buy in 2027
Have you got a question for us?
Contact us if you have any questions about the agenda, team discounts or anything else…